Drug used to treat advanced prostate cancer in short supply, Novartis says

Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week.

Novartis, the pharmaceutical company that manufactures Pluvicto, outlined the causes behind the supply issues in a letter posted by the FDA last month.

In the letter, the company said that it currently only manufactures Pluvicto in Italy in "small batches," and is awaiting FDA approval on a new manufacturing site. That approval was expected to come in four to six months, Novartis said.